SMARCA2 and neoplasm: Interestingly, only the loss of SMARCA2 was found concomitant with the presence of tumor lepidic components and epidermal growth factor receptor (EGFR) mutations, whereas the loss of SMARCA4 was mutually exclusive with those findings [7].